Apollo Hospitals on Thursday launched clinical genomic tests of Strand Life Sciences in all its hospitals.

The tests would be offered in oncology, cardiovascular, heritable eye diseases and rare genetic disorders.

This would be facilitated by Apollo's subsidiary, Sapine Biosciences, its Chief Executive Officer, Sreevatsa Natarajan, told newspersons here on Thursday.

"Genetic diagnostic is not new but what we want to do is actively involve the physican in all possible ways with the latest technology, " he said.

The cost of the tests ranges from Rs 15,000 to Rs 40,000 depending on the nature and specifications.

Dr Vijay Chandru, Chairman & CEO, Strand Life Sciences, said the genomic revolution is helping expanding clinical genomics as a new paradigm for clinical decisions.

Bangalore-based Strand now works with over 50 hospitals and a large network of clinics in Asia and Africa.

Sangita Reddy, Joint Managing Director, Apollo Hospitals, said introduction of genomic tests would help Apollo diagnose and treat patients with more precision.

Genomic testing involves analyses of the patient genomes and translating the insights gained to treat patients as part of personalised medicine.